Medizinische Universit├Ąt Graz - Research portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Rust, C; Bauchmuller, K; Bernt, C; Vennegeerts, T; Fickert, P; Fuchsbichler, A; Beuers, U.
Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.
GUT. 2006; 55(5): 719-727. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar


Authors Med Uni Graz:
Fickert Peter

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Number of Figures: 8
| | | | | | | |
Background: Bile acid induced apoptosis in hepatocytes can be antagonised by nuclear factor kappa B (NF kappa B) dependent survival pathways. Sulfasalazine modulates NFkB in different cell types. We aimed to determine the effects of sulfasalazine and its metabolites sulfapyridine and 5-aminosalicylic acid (5-ASA) on bile acid induced apoptosis in hepatocytes. Methods: Apoptosis was determined by caspase assays and immunoblotting, NFkB activation by electrophoretic mobility shift assay and reporter gene assays, generation of reactive oxygen species (ROS) fluorometrically, bile secretion gravimetrically, and bile acid uptake radiochemically and by gas chromatography in HepG2-Ntcp cells and isolated perfused rat livers. Results: Glycochenodeoxycholic acid (GCDCA 75 mu mol/l) induced apoptosis was reduced by sulfasalazine dose dependently (1-1000 mu mol/l) in HepG2-Ntcp cells whereas its metabolites 5-ASA and sulfapyridine had no effect. Sulfasalazine significantly reduced GCDCA induced activation of caspases 9 and 3. In addition, sulfasalazine activated NFkB and decreased GCDCA induced generation of ROS. Bile acid uptake was competitively inhibited by sulfasalazine. In perfused rat livers, GCDCA (25 mu mol/l) induced liver injury and extensive hepatocyte apoptosis were significantly reduced by simultaneous administration of 100 mu mol/l sulfasalazine: lactate dehydrogenase and glutamate-pyruvate transaminase activities were reduced by 82% and 87%, respectively, and apoptotic hepatocytes were observed only occasionally. GCDCA uptake was reduced by 45 (5)% when sulfasalazine was coadministered. However, when 50% of GCDCA (12.5 mu mol/l) was administered alone, marked hepatocyte apoptosis and liver injury were again observed, questioning the impact of reduced GCDCA uptake for the antiapoptotic effect of sulfasalazine. Conclusion: Sulfasalazine is a potent inhibitor of GCDCA induced hepatocyte apoptosis in vitro and in the intact liver.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Anti-Inflammatory Agents, Non-Steroidal - metabolism Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Apoptosis - drug effects
Caspase 3 -
Caspase 9 -
Caspases - metabolism
Cell Line, Tumor -
Depression, Chemical -
Dose-Response Relationship, Drug -
Fluorescent Antibody Technique -
Glycochenodeoxycholic Acid - pharmacology
Hepatocytes - drug effects Hepatocytes - metabolism Hepatocytes - pathology
Humans -
Liver - drug effects Liver - metabolism Liver - pathology
Male -
Mesalamine - pharmacology
NF-kappa B - metabolism
Perfusion -
Rats -
Rats, Sprague-Dawley -
Sulfapyridine - pharmacology
Sulfasalazine - metabolism Sulfasalazine - pharmacology

© Med Uni GrazImprint